secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-096649
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum reports Q2 2024 net loss $5.0M; PDUFA date Oct 25, 2024; AdCom Sept 9
----------------------------------------------------------------------------

- Net loss $5.0M Q2 2024 (vs $12.2M Q2 2023); cash $11.7M; expects runway into 2025 through PDUFA date.
- FDA PDUFA action date October 25, 2024; Advisory Committee meeting September 9, 2024 on stewardship and patient population.
- Closed rights offering August 9, 2024: $7.4M gross ($5.8M net) from 6.1M shares and warrants.
- Received U.S. and Canadian patent allowances for sulopenem combinations expiring 2039-2041.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024096649/0000950170-24-096649-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024096649/itrm-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096649

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer